547 related articles for article (PubMed ID: 17060208)
21. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
[TBL] [Abstract][Full Text] [Related]
22. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
23. A composite design for transition from a preliminary to a full-scale study.
Lachin JM; Younes N
Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
[TBL] [Abstract][Full Text] [Related]
24. How large should a phase II trial of a new drug be?
Simon R
Cancer Treat Rep; 1987 Nov; 71(11):1079-85. PubMed ID: 3315196
[TBL] [Abstract][Full Text] [Related]
25. Picking the winners in a sea of plenty.
Scher HI; Heller G
Clin Cancer Res; 2002 Feb; 8(2):400-4. PubMed ID: 11839655
[TBL] [Abstract][Full Text] [Related]
26. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
27. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of randomized discontinuation design.
Freidlin B; Simon R
J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib for the treatment of advanced renal cell carcinoma.
Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
[TBL] [Abstract][Full Text] [Related]
30. Trial design for evaluation of novel targeted therapies.
Farley J; Rose PG
Gynecol Oncol; 2010 Feb; 116(2):173-6. PubMed ID: 19853899
[TBL] [Abstract][Full Text] [Related]
31. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
32. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
33. Sample size determination for comparing several survival curves with unequal allocations.
Halabi S; Singh B
Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
[TBL] [Abstract][Full Text] [Related]
34. Other paradigms: randomized discontinuation trial design.
Stadler W
Cancer J; 2009; 15(5):431-4. PubMed ID: 19826364
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
[TBL] [Abstract][Full Text] [Related]
36. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
Mazumdar M; Fazzari M; Panageas KS
Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
[TBL] [Abstract][Full Text] [Related]
37. Selection designs for pilot studies based on survival.
Liu PY; Dahlberg S; Crowley J
Biometrics; 1993 Jun; 49(2):391-8. PubMed ID: 8369375
[TBL] [Abstract][Full Text] [Related]
38. A flexible design for multiple armed screening trials.
Sargent DJ; Goldberg RM
Stat Med; 2001 Apr; 20(7):1051-60. PubMed ID: 11276035
[TBL] [Abstract][Full Text] [Related]
39. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
40. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
